Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Research output: Contribution to journalJournal articleResearchpeer-review

Rune Nielsen, Hannu Kankaanranta, Leif Bjermer, Peter Lange, Sofie Arnetorp, Morten Hedegaard, Anna Stenling, Nicole Mittmann

Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).
Original languageEnglish
JournalRespiratory Medicine
Issue number11
Pages (from-to)1709-21
Number of pages13
Publication statusPublished - Nov 2013

ID: 105585066